guest ::
| Home > Publications Database > Targeting Cdc42 improves motor phenotype in Parkinson’s disease mice and reveals age-dependent susceptibility to α-synuclein > print |
| Home > Publications Database > Targeting Cdc42 improves motor phenotype in Parkinson’s disease mice and reveals age-dependent susceptibility to α-synuclein > print |
| 001 | 282913 | ||
| 005 | 20251217170445.0 | ||
| 024 | 7 | _ | |a 10.1016/j.isci.2025.114217 |2 doi |
| 037 | _ | _ | |a DZNE-2025-01374 |
| 082 | _ | _ | |a 050 |
| 100 | 1 | _ | |a Bopp, Verena |0 P:(DE-2719)9001524 |b 0 |
| 245 | _ | _ | |a Targeting Cdc42 improves motor phenotype in Parkinson’s disease mice and reveals age-dependent susceptibility to α-synuclein |
| 260 | _ | _ | |a St. Louis |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1765974010_5351 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Aging and accumulation of α-synuclein (α-syn) oligomers in the brain are indisputably linked to Parkinson’s disease (PD). Using an inducible α-syn oligomer mouse model, we demonstrate that the induction of PD-associated α-syn oligomers for the same time span caused PD-associated symptoms only in aged, but not in young mice. Biochemical studies revealed that α-syn oligomer formation precedes motor decline, with age and α-syn expression jointly determining the motor phenotype. Single-nucleus RNA sequencing (snRNA-seq) identified a PD-related transcriptional signature in basal ganglia neurons (BGNs), which overlapped in part with aging-associated changes. Short-term pharmacological inhibition of the small RhoGTPase CDC42 in aged, symptomatic animals improved motor function without reducing oligomer levels. These findings indicate that aging processes strongly influence the susceptibility to PD-like symptoms and that targeting age-related pathways, rather than α-syn oligomer burden alone, may provide effective strategies to improve outcomes in PD. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: pub.dzne.de |
| 700 | 1 | _ | |a Lee, Jaehyun |0 P:(DE-2719)9002103 |b 1 |e First author |
| 700 | 1 | _ | |a Oeckl, Patrick |0 P:(DE-2719)9001560 |b 2 |
| 700 | 1 | _ | |a Kühlwein, Julia |0 P:(DE-2719)9001523 |b 3 |
| 700 | 1 | _ | |a Grozdanov, Veselin |0 P:(DE-2719)9001519 |b 4 |
| 700 | 1 | _ | |a Kiechle, Martin |b 5 |
| 700 | 1 | _ | |a Mayer, Benjamin |b 6 |
| 700 | 1 | _ | |a Möhrle, Bettina |b 7 |
| 700 | 1 | _ | |a Geiger, Hartmut |b 8 |
| 700 | 1 | _ | |a Danzer, Karin M. |0 P:(DE-2719)9001513 |b 9 |e Last author |
| 773 | _ | _ | |a 10.1016/j.isci.2025.114217 |g Vol. 28, no. 12, p. 114217 - |0 PERI:(DE-600)2927064-9 |n 12 |p 114217 |t iScience |v 28 |y 2025 |x 2589-0042 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/282913/files/DZNE-2025-01374.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/282913/files/DZNE-2025-01374.pdf?subformat=pdfa |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 0 |6 P:(DE-2719)9001524 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)9002103 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)9001560 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 3 |6 P:(DE-2719)9001523 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 4 |6 P:(DE-2719)9001519 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)9001513 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 1 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-02 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ISCIENCE : 2022 |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-04-12T14:51:15Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-04-12T14:51:15Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-02 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-02 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-04-12T14:51:15Z |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2025-01-02 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ISCIENCE : 2022 |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-02 |
| 920 | 1 | _ | |0 I:(DE-2719)5000072 |k AG Danzer |l Mechanisms of Propagation |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000073 |k AG Öckl |l Translational Mass Spectrometry and Biomarker Research |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)5000072 |
| 980 | _ | _ | |a I:(DE-2719)5000073 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|